

Special Issue

Applications of Cell Signaling and Epigenome Regulation in Cancer Treatment

Message from the Guest Editor

This Special Issue on “Applications of Cell Signaling and Epigenome Regulation in Cancer Treatment” aims to explore applications of cell signaling and epigenome regulation to address cancer cell signaling, progression, metastasis, drug resistance, and therapeutic treatment. Topics include, but are not limited to:

- The exploration of new signaling pathways in cancer;
- The exploration of new tumor epigenomes and epigenetic regulations;
- The study of biomarkers, epigenetic alterations (DNA, RNA, histones), or epigenetic regulatory molecule polymorphisms for tumor therapeutic strategies or prediction;
- The development of tumor-specific models to guide personalized medicine.

Guest Editor

Prof. Dr. Yung-Luen Yu

Institute of New Drug Development, China Medical University, Taichung 404, Taiwan

Deadline for manuscript submissions

closed (30 April 2022)



Processes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5



mdpi.com/si/69886

Processes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
processes@mdpi.com

[mdpi.com/journal/
processes](https://mdpi.com/journal/processes)





Processes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5



[mdpi.com/journal/
processes](https://mdpi.com/journal/processes)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute either a research article or a comprehensive review for consideration and publication in *Processes* (ISSN 2227-9717). *Processes* is published in open access format – research articles, reviews, and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited, free access to the content. As an open access journal, *Processes* is supported by the authors and their institutes through the payment of article processing charges (APCs) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Giancarlo Cravotto

Department of Drug Science and Technology, University of Turin, Via P. Giuria 9, 10125 Turin, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), Ei Compendex, Inspec, AGRIS, and other databases.

Journal Rank:

CiteScore - Q2 (Chemical Engineering (miscellaneous))